Xenoport (NASDAQ:XNPT) is a biopharmaceutical that develops and markets internally discovered candidates with a focus on neurological disorders. Currently the company has a single commercial stage product in the US. Horizant (gabapentin enacarbil) is approved for the treatment of restless legs syndrome (RLS), and postherpetic neuralgia (PHN).
Xenoport shares have been depressed lately, steadily sinking from a high of more than $12.50 in October of 2012, to a recent price of about $4.80. Horizant sales are significant, but hardly enough to bring the company to profitability. In May 2013, failure of its lead candidate to reach its primary endpoint in a Phase 3 trial didn't help any.
Despite the clinical setback, there is a bright glimmer of hope...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|